Summary of Conference Call Notes Company and Industry Involved - The notes pertain to **加科思 (Gakos)**, focusing on its **pan-KRAS inhibitors** and related drug development efforts in the oncology sector. Core Points and Arguments - **Progress of pan-KRAS Inhibitors**: The clinical data for RMC-6236 is reported as excellent, leading to a market capitalization increase of over **$20 billion** for Revolution [1] - **Initial Data for JAB-23E73**: The preliminary data for Gakos' pan-KRAS inhibitor JAB-23E73 shows significant safety advantages, with no grade 3 toxicity observed at the escalated dose level. The incidence of skin toxicity is reported at **10%**, all classified as grade 1, compared to RMC-6236, which has a **90%** incidence of skin toxicity with **8%** at grade 3 [1] - **Collaboration with AstraZeneca**: A collaboration worth **$2 billion** with AstraZeneca is expected to accelerate global progress through a combination treatment approach (IO/ADC) [1] - **Next-Generation ADC Platform**: The next-generation ADC platform is noted to have multi-target and multi-indication expansion potential, with the first candidate drug, EGFRG12DitADC, having its PCC confirmed and an IND submission expected in the second half of **2026** [1][2] - **HER2-STINGiADC Development**: The first candidate drug for iADC, HER2-STINGiADC, has also confirmed its PCC, with an IND submission anticipated in the second half of **2026** [2] - **KRAS G12C Inhibitor**: The KRAS G12C inhibitor, Goretinib, has entered insurance coverage and is rapidly gaining traction, with ongoing registration clinical trials in combination with SHP2 inhibitors for pancreatic and colorectal cancers [2] - **Valuation and Rating**: Based on risk-adjusted DCF calculations, the company is valued at **HKD 8.912 billion**, corresponding to a target price of **HKD 11.26**, with a "strong buy" rating assigned [2] Other Important but Possibly Overlooked Content - The emphasis on safety profiles and the absence of severe toxicity in the new drug candidates may indicate a strategic advantage in competitive positioning within the oncology market [1] - The collaboration with AstraZeneca could enhance the credibility and market reach of Gakos' products, potentially leading to increased investor confidence and market valuation [1] - The anticipated IND submissions for both ADC candidates in **2026** suggest a timeline for future growth and revenue generation, which may be critical for investors to consider [1][2]

Summary of Conference Call Notes Company and Industry Involved - The notes pertain to **加科思 (Gakos)**, focusing on its **pan-KRAS inhibitors** and advancements in the **oncology** sector. Core Points and Arguments - **Progress of pan-KRAS Inhibitors**: The clinical data for RMC-6236 is reported as excellent, leading to a market capitalization increase of over **$20 billion** for Revolution [1] - **Initial Data for JAB-23E73**: The preliminary data for Gakos' pan-KRAS inhibitor JAB-23E73 shows significant safety advantages, with no grade 3 toxicity observed at the escalated dose level and a skin toxicity incidence of **10%** (all grade 1). In comparison, RMC-6236 has a skin toxicity rate of **90%** with **8%** grade 3 toxicity [1] - **Collaboration with AstraZeneca**: A collaboration worth **$2 billion** with AstraZeneca is expected to accelerate global progress through combination therapy approaches (IO/ADC, etc.) [1] - **Next-Generation ADC Platform**: The next-generation ADC platform is noted to have multi-target and multi-indication expansion potential, with the first candidate drug, EGFRG12DitADC, having its PCC confirmed and an IND submission expected in **H2 2026** [1] Additional Important Content - **iADC Candidate Drug**: The first candidate drug for iADC, HER2-STINGiADC, has also confirmed its PCC, with an IND submission anticipated in **H2 2026** [2] - **KRAS G12C Inhibitor**: The KRAS G12C inhibitor, Goretinib, has entered the medical insurance coverage, showing rapid volume growth. Clinical registrations are ongoing for its combination with SHP2 inhibitors in pancreatic and colorectal cancers [2] - **Valuation and Rating**: Based on risk-adjusted DCF calculations, the company is valued at **HKD 8.912 billion**, corresponding to a target price of **HKD 11.26**, with a "strong buy" rating [2]